Up to date, a large number of studies have uncovered multiple genes can serve as biomarkers for immunotherapy response in BrCa or other cancer types, such as CCDC69 (Yi et al., 2022), TIMM8A (Zhang et al., 2022b), and ACE2 (Mei et al., 2022). This evidence concerns the gene ACE2 and invasive breast carcinoma.